Karyopharm Therapeutics (KPTI)
(Delayed Data from NSDQ)
$1.14 USD
-0.01 (-0.87%)
Updated May 20, 2024 04:00 PM ET
After-Market: $1.14 0.00 (0.00%) 4:32 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Brokerage Reports
Karyopharm Therapeutics Inc. [KPTI]
Reports for Purchase
Showing records 61 - 80 ( 386 total )
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 3 XPORT-MM-031 Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Positive CHMP Opinion For Nexpovio (selinexor) in Refractory Multiple Myeloma
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Initial Data From Study of Xpovio in Combination With Jakafi in MF to be Presented at EHA
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
1Q22 Earnings; CHMP Opinion Expected 2Q22; Looking to Myelofibrosis Data at ASCO
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Phase 3 SIENDO Data Highlighted in Presentation at ESMO Virtual Plenary
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 4.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 25.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
The FDA Gives Selinexor a Siesta Based on SIENDO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Another Study Required for FDA Submission of Xpovio in Endometrial Cancer
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
4Q21 Results; Excellent Xpovio Phase 3 SIENDO Data; 2022 Catalysts Abound
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
FDA Grants Orphan Drug Designation for Eltanexor in MDS
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Preliminary 4Q21 Xpovio Net Product Sales Exceed Expectations
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
Nexpovio Licensing Agreement to Commercialize in Europe and Other Key Global Territories Announced
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Karyopharm Therapeutics Inc.
Industry: Medical - Drugs
New Partnership with Eye Towards NEXPOVIO EU Launch
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D